ArticleInfection and immunity2006
Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.
Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Meta-Analysis and Advancement of Brucellosis Vaccinology.PloS one · 2016Pooled it
- An orthogonal transcription system enables high-efficiency rescue of measles virus-based vaccine vectors against multiple pathogens.Synthetic and systems biotechnology · 2027Article
- The Role of Outer Membrane Protein 16 inVeterinary sciences · 2025Review
- A novel IgG-Fc-Fused multiepitope vaccine against Brucella: robust immunogenicity.Microbial cell factories · 2025Article
- Intranasal trivalent candidate vaccine elicits broad humoral and cellular immunity against pneumococcal pneumonia.Frontiers in cellular and infection microbiology · 2025Article
- Bioinformatics analysis of the antigenic epitopes of L7/L12 protein in the B- and T-cells active against Brucella melitensis.Access microbiology · 2024Article
- Brucellae as resilient intracellular pathogens: epidemiology, host-pathogen interaction, recent genomics and proteomics approaches, and future perspectives.Frontiers in veterinary science · 2023Review
- Development of a diagnostic indirect ELISA test for detection ofVeterinary research forum : an international quarterly journal · 2022Article
- Immunization with a combination of recombinant Brucella abortus proteins induces T helper immune response and confers protection against wild-type challenge in BALB/c mice.Microbial biotechnology · 2022Article
- Evaluation of Brucellosis Vaccines: A Comprehensive Review.Frontiers in veterinary science · 2022Review
- Proteomic and Antibody Profiles Reveal Antigenic Composition and Signatures of Bacterial Ghost Vaccine ofFrontiers in immunology · 2022Article
- Registered Influenza Viral Vector BasedFrontiers in cellular and infection microbiology · 2021Article
- RNA-Seq Analysis Reveals the Role of Omp16 inFrontiers in veterinary science · 2021Article
- Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis andIranian journal of biotechnology · 2021Article
- Article
- Omp16, a conserved peptidoglycan-associated lipoprotein, is involved in Brucella virulence in vitro.Journal of microbiology (Seoul, Korea) · 2020Article
- Comparison of Immune Effects BetweenFrontiers in veterinary science · 2020Article
- Development of new generation of vaccines forHeliyon · 2018Review
- Immunogenicity evaluation of plasmids encodingIranian journal of basic medical sciences · 2018Article
- Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.Iranian journal of basic medical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein) and Omp16 protein (outer membrane lipoprotein), designated pcDNA3.1-L7/L12-Omp16. Intramuscular injection of this divalent DNA vaccine into BALB/c mice elicited markedly both humoral and cellular immune responses. The specific antibodies exhibited a dominance of immunoglobulin G2a (IgG2a) over IgG1. In addition, the dual-gene DNA vaccine elicited a strong T-cell proliferative response and induced a large amount of gamma interferon-producing T cells upon restimulation in vitro with recombinant fusion protein L7/L12-Omp16, suggesting the induction of a typical T-helper-1-dominated immune response in vivo. This divalent DNA vaccine could also induce a significant level of protection against challenge with the virulent strain B. abortus 544 in BALB/c mice. Furthermore, the protection level induced by the divalent DNA vaccine was significantly higher than that induced by the univalent DNA vaccines pcDNA3.1-L7/L12 or pcDNA3.1-Omp16. Taken together, the results of this study verify for the first time that the Omp16 gene can be a candidate target for a DNA vaccine against brucellosis. Additionally, a divalent genetic vaccine based on the L7/L12 and Omp16 genes can elicit a stronger cellular immune response and better immunoprotection than the relevant univalent vaccines can.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.